{"id":50598,"date":"2022-11-08T12:02:29","date_gmt":"2022-11-08T11:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"modified":"2022-11-08T12:02:29","modified_gmt":"2022-11-08T11:02:29","slug":"turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","title":{"rendered":"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"},"content":{"rendered":"
\n

\nPreclinical data support the clinical potential of Turnstone\u2019s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies<\/i>\n<\/p>\n

<\/a><\/p>\n

\nPresentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies<\/i>\n<\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#SITC2022<\/a>–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, today announced that two posters showing preclinical data from the Company\u2019s novel tumor-infiltrating lymphocyte (TIL) therapy will be presented at the Society for Immunotherapy of Cancer (SITC) 37th<\/sup> Annual Meeting, being held in Boston, Massachusetts, November 8-12, 2022.\n<\/p>\n

\nThe posters, one of which is to be presented in collaboration with Moffitt Cancer Center, will showcase data demonstrating the successful expansion and enrichment of tumor-reactive TILs from colorectal cancer tumor samples, providing support for the application of TIDAL-01 as a therapy for solid tumors. TIDAL-01, Turnstone\u2019s lead TIL therapy candidate, focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) to overcome the limitations of current TIL-based therapies.\n<\/p>\n

\n\u201cOver the years, we have witnessed remarkable durable responses in a limited number of solid tumor types following treatment with TILs<\/i>,\u201d said Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics. \u201cOur preclinical datasets demonstrate greater promise for our Selected TILs compared to conventional TIL-based therapies to target a broader range of solid tumors. With our recently accepted INDs for TIDAL-01, we are eager to translate these promising results into the clinic, including through our strategic alliance with Moffitt.<\/i>\u201d\n<\/p>\n

\nThe full abstracts are available on the SITC website, and details of the poster presentations are as follows:\n<\/p>\n

\nPresented jointly with Moffitt Cancer Center
\n
<\/i>Title<\/b>: Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal cancer (CRC)
\n
Session<\/b>: Cellular Therapies
\n
Session Date and Time<\/b>: November 10, 2022, 9:00 a.m. \u2013 9:00 p.m.
\n
Location<\/b>: Poster Hall C
\n
Abstract Number<\/b>: 387\n<\/p>\n

\nTurnstone presentation
\n
<\/i>Title<\/b>: Enrichment of neoantigen reactive TIL in a CRC patient sample by FACS: The TIDAL-01 process
\n
Session<\/b>: Cellular Therapies
\n
Session Date and Time<\/b>: November 11, 2022, 9:00 a.m. \u2013 8:30 p.m.
\n
Location<\/b>: Poster Hall C
\n
Abstract Number<\/b>: 404\n<\/p>\n

\nAbout Turnstone Biologics<\/b>\n<\/p>\n

\nTurnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering a differentiated approach with a clinically validated technology, tumor infiltrating lymphocyte (TIL) therapy. Turnstone\u2019s innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the Company\u2019s foundational therapeutic modality driving its cancer immunotherapy pipeline. The Company\u2019s lead Selected TIL therapy candidate, TIDAL-01, is expected to initiate clinical trials in 2022. Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.\n<\/p>\n

\nFor more information, please visit www.turnstonebio.com<\/a>, and follow us on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAhmed Aneizi
\n
Turnstone Biologics
\n
(347) 897-5988
\n
ahmed.aneizi@turnstonebio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Preclinical data support the clinical potential of Turnstone\u2019s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies SAN DIEGO–(BUSINESS WIRE)–#SITC2022–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50598","6":"format-standard","7":"category-industry"},"yoast_head":"\nTurnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Preclinical data support the clinical potential of Turnstone\u2019s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies SAN DIEGO–(BUSINESS WIRE)–#SITC2022–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T11:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221108005534\/en\/1628982\/21\/TSTN_Logo_Twitter.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\",\"datePublished\":\"2022-11-08T11:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"},\"wordCount\":517,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005534\\\/en\\\/1628982\\\/21\\\/TSTN_Logo_Twitter.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\",\"name\":\"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005534\\\/en\\\/1628982\\\/21\\\/TSTN_Logo_Twitter.jpg\",\"datePublished\":\"2022-11-08T11:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005534\\\/en\\\/1628982\\\/21\\\/TSTN_Logo_Twitter.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005534\\\/en\\\/1628982\\\/21\\\/TSTN_Logo_Twitter.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend","og_description":"Preclinical data support the clinical potential of Turnstone\u2019s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies SAN DIEGO–(BUSINESS WIRE)–#SITC2022–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-08T11:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221108005534\/en\/1628982\/21\/TSTN_Logo_Twitter.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting","datePublished":"2022-11-08T11:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"},"wordCount":517,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221108005534\/en\/1628982\/21\/TSTN_Logo_Twitter.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/","name":"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221108005534\/en\/1628982\/21\/TSTN_Logo_Twitter.jpg","datePublished":"2022-11-08T11:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221108005534\/en\/1628982\/21\/TSTN_Logo_Twitter.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221108005534\/en\/1628982\/21\/TSTN_Logo_Twitter.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-from-novel-til-therapy-demonstrating-tumor-reactive-t-cell-selection-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50598"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50598\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}